액츄에이트 테라퓨틱스(ACTU)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.01 (+3.58%), 시가총액 $0.06B, 52주 범위 $1.72 ~ $11.90.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is h
액츄에이트 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
액츄에이트 테라퓨틱스의 현재 주가는 $1.01 (+3.58%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
액츄에이트 테라퓨틱스의 시가총액은 약 $0.06B입니다.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injecti